January 10, 2017
Novo Nordisk’s diabetes drug available in Europe in the first half of 2017
European Commission has granted marketing authorisation for Novo Nordisk’s Fiasp for the treatment of diabetes in adults.
Pharmaceuticals, Biotechnology and Life Sciences
European Commission has granted marketing authorisation for Novo Nordisk’s Fiasp for the treatment of diabetes in adults.